Key result
Tranilast suppresses intimal hyperplasia and vascular smooth muscle cell proliferation in preclinical vascular injury models.
Why the study?
Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA), and the effects of tranilast on this condition were investigated.
Tranilast merits clinical trials for post-PTCA restenosis prevention; leaves open translation from rabbit models to humans.
Intimal hyperplasia is a serious problem after percutaneous transluminal coronary angioplasty (PTCA). In this study, we investigated the effects of tranilast on intimal hyperplasia in both in vivo and in vitro experiments. For the in vivo experiments, we used the balloon injury model and the cuff treatment model of rabbits fed regular chow. In the balloon injury model, tranilast decreased intimal area, intima/media ratio, stenosis ratio and vascular DNA content after endothelial injury. Also in the cuff treatment model, tranilast suppressed the intimal hyperplasia. In the in vitro experiments, we assessed the effects of tranilast on platelet-derived growth factor-induced rabbit vascular smooth muscle cell (VSMC) migration and proliferation and on collagen synthesis by VSMCs. Tranilast inhibited VSMC migration, proliferation and collagen synthesis. These results suggest that tranilast has a suppressive effect on intimal hyperplasia after a vascular injury such as PTCA.
No takes yet. Share an insight, caveat, or question.
Fukuyama et al. (1996) studied Intimal hyperplasia. Tranilast was evaluated on Intimal area, intima/media ratio, stenosis ratio, vascular DNA content, and VSMC migration, proliferation, and collagen synthesis. Tranilast suppressed intimal hyperplasia in rabbit balloon injury and cuff treatment models, and inhibited vascular smooth muscle cell migration, proliferation, and collagen synthesis in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: